Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
17
APVO Quote, Financials, Valuation and Earnings
Last price:
$0.93
Seasonality move
:
-19.09%
Day range:
$0.91 - $1.04
52-week range:
$0.91 - $109.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.04x
P/B ratio:
0.17x
Volume:
910.4K
Avg. volume:
950.4K
1-year change:
-99.04%
Market cap:
$3M
Revenue:
--
EPS (TTM):
-$185.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
-- | -$2.09 | -- | -99.48% | $21.00 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
$0.93 | $21.00 | $3M | -- | $0.00 | 0% | 0.04x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.75 | $0.85 | $598.6M | 7.98x | $0.80 | 0% | 9.23x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.84 | $2.00 | $687.2K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
18.66% | 2.902 | 85.35% | 3.75x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APVO
Aptevo Therapeutics, Inc.
|
-$49K | -$7.6M | -260.27% | -442.03% | -- | -$6.7M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Aptevo Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns APVO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of -255.85%. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About APVO or NBY?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 2157.82%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.11%. Given that Aptevo Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is APVO or NBY More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.419, which suggesting that the stock is 41.867% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock APVO or NBY?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or NBY?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 7.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 9.23x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M NBYNovaBay Pharmaceuticals, Inc.9.23x 7.98x $521K -$1.3M
-
Which has Higher Returns APVO or NNVC?
NanoViricides, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About APVO or NNVC?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 2157.82%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that Aptevo Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is APVO or NNVC More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.419, which suggesting that the stock is 41.867% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock APVO or NNVC?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or NNVC?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns APVO or OGEN?
Oragenics, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About APVO or OGEN?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 2157.82%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 139.49%. Given that Aptevo Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Aptevo Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is APVO or OGEN More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.419, which suggesting that the stock is 41.867% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock APVO or OGEN?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or OGEN?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns APVO or PTN?
Palatin Technologies has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About APVO or PTN?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 2157.82%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Aptevo Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Aptevo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is APVO or PTN More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.419, which suggesting that the stock is 41.867% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock APVO or PTN?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or PTN?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is higher than Palatin Technologies's net income of --. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns APVO or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to Aptevo Therapeutics, Inc.'s net margin of --. Aptevo Therapeutics, Inc.'s return on equity of -442.03% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital APVOAptevo Therapeutics, Inc.-- -$2.23 $21.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About APVO or TOVX?
Aptevo Therapeutics, Inc. has a consensus price target of $21.00, signalling upside risk potential of 2157.82%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3497.12%. Given that Theriva Biologics, Inc. has higher upside potential than Aptevo Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Aptevo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APVOAptevo Therapeutics, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is APVO or TOVX More Risky?
Aptevo Therapeutics, Inc. has a beta of 1.419, which suggesting that the stock is 41.867% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock APVO or TOVX?
Aptevo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aptevo Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APVO or TOVX?
Aptevo Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Aptevo Therapeutics, Inc.'s net income of -$9M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Aptevo Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aptevo Therapeutics, Inc. is 0.04x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APVOAptevo Therapeutics, Inc.0.04x -- -- -$9M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 26
Travere Therapeutics, Inc. [TVTX] is down 1.29% over the past day.
Buy
68
KOD alert for Dec 26
Kodiak Sciences, Inc. [KOD] is down 5.28% over the past day.
Buy
64
ZCSH alert for Dec 23
Grayscale Zcash Trust (ZEC) [ZCSH] is down 0% over the past day.
